Abeona Therapeutics Inc. (LON:0H7R)
London
· Delayed Price · Currency is GBP · Price in USD | Market Cap | 192.35M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -50.91M |
| Shares Out | n/a |
| EPS (ttm) | -1.24 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,939 |
| Average Volume | 29,010 |
| Open | 5.49 |
| Previous Close | 5.47 |
| Day's Range | 5.34 - 5.54 |
| 52-Week Range | 2.35 - 8.80 |
| Beta | 1.70 |
| RSI | 50.24 |
| Earnings Date | May 13, 2025 |
About Abeona Therapeutics
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is pz-cel, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform progra... [Read more]
News
Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease
Abeona Therapeutics Inc. 's (NASDAQ: ABEO) stock traded higher on Wednesday. The Food and Drug Administration (FDA) on Tuesday approved Abeona’s Zevaskyn (prademagene zamikeracel) gene-modified cellu...
Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease
Abeona Therapeutics Inc.'s ABEO stock traded higher on Wednesday.
Abeona Stock Surges to 52-Week High: What's Behind The Move?
Abeona shares are trading higher on ... Full story available on Benzinga.com
Abeona Therapeutics Wins FDA Approval For First-of-Its-Kind Gene Therapy
FDA approves Zevaskyn as the first ... Full story available on Benzinga.com
Abeona spikes on FDA nod for gene therapy
US FDA approves Abeona's skin disorder therapy
The U.S. Food and Drug Administration on Tuesday approved Abeona Therapeutics' gene therapy for a rare skin disorder.
U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
- ZEVASKYN fills a critical need for people living with RDEB, a debilitating dermatological condition with no cure - - Approval based on the pivotal Phase 3 VIITAL™ study, showing ZEVASKYN resulted in...
Undercovered Dozen: 3D Systems, Seritage, Topicus, Timken +
The 'Undercovered' Dozen highlights 12 lesser-covered stocks, offering investment opportunities and fostering community discussion on their potential. Abeona Therapeutics is seen as a Buy due to promi...
Abeona Therapeutics: pz-cel Has Massive Potential For RDEB Patients
Abeona Therapeutics: An Uncertain Pivotal Regulatory Catalyst With Limited Long-Term Upside
Abeona Therapeutics: A Buy With Major PDUFA Catalyst On April 29 That Should Send Shares Higher
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, April 01, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awa...
Abeona Therapeutics Inc. 2024 Q4 - Results - Earnings Call Presentation
Abeona Therapeutics targets $2B revenue potential for pz-cel amid U.S. launch preparations
Abeona Therapeutics Inc. (ABEO) Q4 2024 Earnings Call Transcript
Abeona Therapeutics GAAP EPS of -$1.55 beats by $0.21
Abeona Therapeutics (ABEO) reports improved FY EPS, strong cash position of $98.1M, and sufficient funding into 2026.
Abeona Therapeutics® Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch Plans
FDA priority review of pz-cel Biologics License Application (BLA) progressing with Prescription Drug User Fee Act (PDUFA) target action date of April 29, 2025
Abeona Therapeutics® to Present at the Leerink Partners Global Healthcare Conference
CLEVELAND, March 04, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Abeona's Chief Executive Officer, Vish Seshadri, Ph.D., M.B.A., will present at the Leerink P...
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, March 03, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awa...
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awar...
Abeona Therapeutics: Despite Some Competitive Pressure, This Looks Undervalued
Abeona Therapeutics Inc.'s promising gene therapy for RDEB, potential FDA approval, undervalued stock, and key risks. Click for our ABEO stock update.
Insider Sell: Mark Alvino Sells 4,000 Shares of Abeona Therapeutics Inc (ABEO)
Insider Sell: Mark Alvino Sells 4,000 Shares of Abeona Therapeutics Inc (ABEO)
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, , Dec. 31, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity aw...
Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
FDA accepts BLA resubmission of pz-cel in recessive dystrophic epidermolysis bullosa and sets PDUFA target action date of April 29, 2025
Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa
CLEVELAND, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Abeona's resubmission of i...